Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463221 | 0.83 | KCNA5 (0.34) | SMN1; SMN2KCNA5 | |
| SCHEMBL4464202 | 0.80 | CFTR (0.59) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4458259 | 0.77 | CFTR (0.55) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4464162 | 0.77 | KCNA5 (0.48) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4461894 | 0.76 | KCNA5 (0.51) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4454560 | 0.76 | SLC6A2 (0.41) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4463317 | 0.76 | CFTR (0.53) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4457222 | 0.74 | TAAR1 (0.43) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL4459337 | 0.74 | CFTR (0.55) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 | |
| SCHEMBL14435411 | 0.72 | CFTR (0.50) | SMN1; SMN2CFTRGOPCSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | SMN1; SMN2 3817/4885CFTR 520/4885GOPC 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.